全文获取类型
收费全文 | 11811篇 |
免费 | 1153篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 141篇 |
儿科学 | 271篇 |
妇产科学 | 479篇 |
基础医学 | 1843篇 |
口腔科学 | 204篇 |
临床医学 | 1507篇 |
内科学 | 2131篇 |
皮肤病学 | 152篇 |
神经病学 | 1179篇 |
特种医学 | 453篇 |
外科学 | 1327篇 |
综合类 | 300篇 |
一般理论 | 13篇 |
预防医学 | 1186篇 |
眼科学 | 230篇 |
药学 | 825篇 |
中国医学 | 15篇 |
肿瘤学 | 725篇 |
出版年
2022年 | 101篇 |
2021年 | 222篇 |
2020年 | 154篇 |
2019年 | 201篇 |
2018年 | 242篇 |
2017年 | 156篇 |
2016年 | 223篇 |
2015年 | 216篇 |
2014年 | 302篇 |
2013年 | 439篇 |
2012年 | 685篇 |
2011年 | 743篇 |
2010年 | 386篇 |
2009年 | 349篇 |
2008年 | 612篇 |
2007年 | 556篇 |
2006年 | 586篇 |
2005年 | 626篇 |
2004年 | 602篇 |
2003年 | 519篇 |
2002年 | 502篇 |
2001年 | 334篇 |
2000年 | 335篇 |
1999年 | 267篇 |
1998年 | 127篇 |
1997年 | 96篇 |
1996年 | 104篇 |
1995年 | 129篇 |
1994年 | 113篇 |
1993年 | 89篇 |
1992年 | 212篇 |
1991年 | 183篇 |
1990年 | 209篇 |
1989年 | 207篇 |
1988年 | 186篇 |
1987年 | 159篇 |
1986年 | 142篇 |
1985年 | 124篇 |
1984年 | 130篇 |
1983年 | 94篇 |
1982年 | 70篇 |
1980年 | 69篇 |
1979年 | 128篇 |
1978年 | 96篇 |
1977年 | 71篇 |
1976年 | 72篇 |
1975年 | 64篇 |
1974年 | 90篇 |
1973年 | 73篇 |
1972年 | 79篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Christopher D Hue Frances S Cho Siqi Cao Cameron R ”Dale” Bass David F Meaney Barclay Morrison III 《Journal of cerebral blood flow and metabolism》2015,35(7):1191-1198
Owing to the frequent incidence of blast-induced traumatic brain injury (bTBI) in recent military conflicts, there is an urgent need to develop effective therapies for bTBI-related pathologies. Blood-brain barrier (BBB) breakdown has been reported to occur after primary blast exposure, making restoration of BBB function and integrity a promising therapeutic target. We tested the hypothesis that treatment with dexamethasone (DEX) after primary blast injury potentiates recovery of an in vitro BBB model consisting of mouse brain endothelial cells (bEnd.3). DEX treatment resulted in complete recovery of transendothelial electrical resistance and hydraulic conductivity 1 day after injury, compared with 3 days for vehicle-treated injured cultures. Administration of RU486 (mifepristone) inhibited effects of DEX, confirming that barrier restoration was mediated by glucocorticoid receptor signaling. Potentiated recovery with DEX treatment was accompanied by stronger zonula occludens (ZO)-1 tight junction immunostaining and expression, suggesting that increased ZO-1 expression was a structural correlate to BBB recovery after blast. Interestingly, augmented ZO-1 protein expression was associated with specific upregulation of the α+ isoform but not the α− isoform. This is the first study to provide a mechanistic basis for potentiated functional recovery of an in vitro BBB model because of glucocorticoid treatment after primary blast injury. 相似文献
2.
3.
4.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
5.
Understanding the contribution of endothelial cells to the progenitor pools of adult tissues has the potential to inform therapies for human disease.To address whether endothelial cells transdifferentiate into non-vascular cell types,we performed cell lineage tracing analysis using transgenic mice engineered to express a fluorescent marker following activation by tamoxifen in vascular endothelial cadherin promoter-expressing cells(VEcad-CreERT2;B6 Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze).Activation of target-cell labeling following 1.5 months of ad libitum feeding with tamoxifen-laden chow in 4–5 month-old mice resulted in the tracing of central nervous system and peripheral cells that include:cerebellar granule neurons,ependymal cells,skeletal myocytes,pancreatic beta cells,pancreatic acinar cells,tubular cells in the renal cortex,duodenal crypt cells,ileal crypt cells,and hair follicle stem cells.As Nestin expression has been reported in a subset of endothelial cells,Nes-CreERT2 mice were also utilized in these conditions.The tracing of cells in adult Nes-CreERT2 mice revealed the labeling of canonical progeny cell types such as hippocampal and olfactory granule neurons as well as ependymal cells.Interestingly,Nestin tracing also labeled skeletal myocytes,ileal crypt cells,and sparsely marked cerebellar granule neurons.Our findings provide support for endothelial cells as active contributors to adult tissue progenitor pools.This information could be of particular significance for the intravenous delivery of therapeutics to downstream endothelial-derived cellular targets.The animal experiments were approved by the Boise State University Institute Animal Care and Use Committee(approval No.006-AC15-018)on October 31,2018. 相似文献
6.
7.
Annals of Surgical Oncology - 相似文献
8.
9.
10.